Every financial statement,
one clean chart.
Search any US-listed company. Data straight from SEC filings.
HALOZYME THERAPEUTICS, INC. (HALO), most recent 12 months reported: revenue $1.66B, net income $413.6M, free cash flow $806.22M. Latest balance sheet on file: liquid cash $231M, total debt $2.15B, net cash -$1.92B. From SEC filings. More on HALOZYME THERAPEUTICS, INC.: Revenue · Profitability · Cash flow · Debt Others in Biological Products, (No Diagnostic Substances): NEUROCRINE BIOSCIENCES INC · Exelixis Inc · Moderna, Inc. · QIAGEN N.V. · BIO-TECHNE Corp · BIOCRYST PHARMACEUTICALS, INC. · REPLIGEN CORP · TARSUS PHARMACEUTICALS, INC.
Filter every US company by the numbers — net cash, margins, ROIC, growth. Looking for one company? The search box above is free.
Follow a company and we'll email you when it files a quarterly or annual report with the SEC. Free follows 3 companies; Pro follows up to 500, and sorts and filters them.